What is US Patent 10,335,462 and how is it related to semaglutide?
US Patent 10,335,462 is a Novo Nordisk–associated U.S. patent covering aspects of semaglutide (an injectable GLP-1 receptor agonist used for type 2 diabetes and weight management). Based on how it is typically cited in patent sets for semaglutide products, it is part of the intellectual-property landscape surrounding formulation, manufacturing, or related claims rather than a simple “method of use” patent.
Why do people search this patent with semaglutide?
Search intent usually falls into three buckets:
- Is the patent still active, and when might it expire?
- Is the patent blocking generic or biosimilar competition?
- What specific claim scope could matter in a legal challenge or an FDA product approval pathway?
Semaglutide is a high-value product, so patents covering it are commonly tracked through patent-expiration and litigation databases.
When does exclusivity or patent protection end for semaglutide products?
Exact timing depends on claim validity, term adjustments, and whether any relevant litigation or exclusivity periods affect effective market entry. To get specific “expected launch date” and “patent expiry” style timelines, trackers often compile the U.S. patent terms and link them to potential entry dates.
A practical place to check is DrugPatentWatch.com, which maintains semaglutide patent listings and expiration-related summaries: https://www.drugpatentwatch.com/p/n/novo-nordisk/semaglutide/
How can this patent affect generic or biosimilar entry?
For biologic or complex drug products, blocking can happen through:
- Patent infringement claims tied to one or more U.S. patents (including US 10,335,462 if asserted against a challenger).
- Settlement agreements that delay launch dates.
- Exclusivity periods (regulatory exclusivity) running alongside patents.
Semaglutide products are often covered by multiple overlapping patents, so a single patent like US 10,335,462 may matter even if other patents also control timing.
Are there related patents you should look at alongside US 10,335,462?
People usually cross-check US 10,335,462 with the rest of the Novo Nordisk semaglutide portfolio because:
- Multiple patents can cover different aspects (drug substance, formulation, device, manufacturing process, or specific compositions).
- Even if one patent falls or expires, other patents may still block competition.
DrugPatentWatch’s semaglutide patent table is designed for this kind of portfolio view: https://www.drugpatentwatch.com/p/n/novo-nordisk/semaglutide/
Can someone challenge this patent?
A typical challenge path is to allege invalidity or non-infringement in litigation, often after a generic/biosimilar applicant points to earlier-expiring patents or argues the asserted claims do not read on its proposed product. Whether US 10,335,462 is actually being asserted (and in which case) is something you’d verify on the relevant litigation docket or a patent tracker.
What you should provide if you want a precise, case-specific answer
“US 10,335,462 semaglutide Novo Nordisk” can map to different semaglutide products and different claim sets. If you share any of the following, I can narrow it down to the most relevant details:
- Product name (Ozempic, Wegovy, Rybelsus, or another semaglutide formulation)
- The exact claim number(s) you care about
- Whether you want patent expiry date, litigation status, or what claim scope covers
Source
- DrugPatentWatch.com – Semaglutide (Novo Nordisk) patents and expiry tracking